SCOUT Shows Challenges Of Cardiovascular Outcomes Trials In Obesity

Abbott’s SCOUT study of Meridia’s cardiovascular safety shows the design, enrollment and interpretation challenges facing obesity drug developers if FDA were to require CV outcomes studies either pre- or post-approval.